| Q42333514 | 2nd PEGS Annual Symposium on Antibodies for Cancer Therapy: April 30-May 1, 2012, Boston, USA. |
| Q34204188 | A General Approach for Receptor and Antibody-Targeted Detection of Native Proteins Utilizing Split-Luciferase Reassembly |
| Q28596313 | A Physical Mechanism and Global Quantification of Breast Cancer |
| Q39027277 | A Single-Chain Antibody Using LoxP511 as the Linker Enables Large-Content Phage Library Construction via Cre/LoxP Recombination. |
| Q38642011 | A Tri-part Protein Complementation System Using Antibody-Small Peptide Fusions Enables Homogeneous Immunoassays |
| Q34422576 | A conformationally constrained peptidomimetic binds to the extracellular region of HER2 protein |
| Q35682599 | A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK. |
| Q36062442 | A growing family: adding mutated Erbb4 as a novel cancer target |
| Q26860116 | A high-throughput shotgun mutagenesis approach to mapping B-cell antibody epitopes |
| Q36748708 | A monoclonal antibody targeting ErbB2 domain III inhibits ErbB2 signaling and suppresses the growth of ErbB2-overexpressing breast tumors. |
| Q58593563 | A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study |
| Q35624686 | A multiscale systems perspective on cancer, immunotherapy, and Interleukin-12 |
| Q28257173 | A new therapeutic antibody masks ErbB2 to its partners |
| Q57628597 | A novel ErbB2 epitope targeted by human antitumor immunoagents |
| Q99574593 | A novel HER2-targeting antibody 5G9 identified by large-scale trastuzumab-based screening exhibits potent synergistic antitumor activity |
| Q26824462 | A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy |
| Q44114723 | A peptidomimetic with a chiral switch is an inhibitor of epidermal growth factor receptor heterodimerization. |
| Q34077853 | A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer |
| Q34051972 | A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer |
| Q37078963 | A plant-expressed conjugate vaccine breaks CD4(+) tolerance and induces potent immunity against metastatic Her2(+) breast cancer |
| Q41344028 | A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience |
| Q36730394 | A splice variant of HER2 corresponding to Herstatin is expressed in the noncancerous breast and in breast carcinomas |
| Q35674768 | A structural perspective on the regulation of the epidermal growth factor receptor |
| Q64928480 | A toolkit for studying cell surface shedding of diverse transmembrane receptors. |
| Q34317299 | ACK1 tyrosine kinase interacts with histone demethylase KDM3A to regulate the mammary tumor oncogene HOXA1 |
| Q53701267 | Acquired Resistance to Drugs Targeting Tyrosine Kinases. |
| Q38551607 | Activated ErbB3 Translocates to the Nucleus via Clathrin-independent Endocytosis, Which Is Associated with Proliferating Cells |
| Q54986604 | Activating HER2 mutations as emerging targets in multiple solid cancers. |
| Q27851987 | Activating HER2 mutations in HER2 gene amplification negative breast cancer |
| Q36785721 | Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment |
| Q34483533 | Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice |
| Q24600031 | Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab |
| Q37601692 | Advances and future directions in the targeting of HER2-positive breast cancer: implications for the future. |
| Q37777142 | Advances in novel drug delivery strategies for breast cancer therapy. |
| Q38206546 | Advances in the approach to novel drug clinical development for breast cancer |
| Q50084900 | Advances in the management of HER2-positive early breast cancer |
| Q42908395 | Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses |
| Q39022761 | Affinity maturation of an ERBB2-targeted SPECT imaging peptide by in vivo phage display |
| Q34419541 | Affinity maturation of antiHER2 monoclonal antibody MIL5 using an epitope-specific synthetic phage library by computational design |
| Q53082766 | Allosteric modulation as a unifying mechanism for receptor function and regulation. |
| Q39493859 | An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling. |
| Q27667776 | An anti-hapten camelid antibody reveals a cryptic binding site with significant energetic contributions from a nonhypervariable loop |
| Q93079107 | An in vitro FcRn- dependent transcytosis assay as a screening tool for predictive assessment of nonspecific clearance of antibody therapeutics in humans |
| Q34061140 | Anatomy of β-strands at protein-protein interfaces |
| Q52684454 | Anti-HER2 scFv-Directed Extracellular Vesicle-Mediated mRNA-Based Gene Delivery Inhibits Growth of HER2-Positive Human Breast Tumor Xenografts by Prodrug Activation. |
| Q34140167 | Antibodies and Tyrosine Kinase Inhibitors in Breast Cancer Therapies |
| Q38688747 | Antibodies as stratagems against cancer |
| Q36791878 | Antibody Therapeutics in Oncology |
| Q31104000 | Antibody Therapies in Cancer |
| Q54252199 | Antibody response to HER2 extracellular domain and subdomains in mouse following DNA immunization. |
| Q37479212 | Antibody validation |
| Q38404913 | Antibody validation by combining immunohistochemistry and protein extraction from formalin-fixed paraffin-embedded tissues |
| Q39865068 | Antitumor activity of the HER2 dimerization inhibitor pertuzumab on human colon cancer cells in vitro and in vivo |
| Q90247804 | Assessment of the Molecular Mechanism of Action of SB3, a Trastuzumab Biosimilar |
| Q37224335 | Autoantibodies as biomarkers for ovarian cancer |
| Q35653820 | Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer |
| Q36285897 | Binding of trastuzumab to ErbB2 is inhibited by a high pericellular density of hyaluronan |
| Q92714198 | Bioinformatics Analysis of Potential Key Genes in Trastuzumab-Resistant Gastric Cancer |
| Q33895597 | Biologic therapy in esophageal and gastric malignancies: current therapies and future directions |
| Q37633741 | Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer |
| Q49329183 | Biophysical Evidence for Intrinsic Disorder in the C-terminal Tails of the Epidermal Growth Factor Receptor (EGFR) and HER3 Receptor Tyrosine Kinases |
| Q48455124 | Bleomycin-induced pulmonary fibrosis is attenuated by a monoclonal antibody targeting HER2. |
| Q38885404 | Blockade of a key region in the extracellular domain inhibits HER2 dimerization and signaling. |
| Q36821263 | Bovine herpesvirus 4-based vector delivering a hybrid rat/human HER-2 oncoantigen efficiently protects mice from autochthonous Her-2(+) mammary cancer |
| Q48140622 | Bridging oncology and immunology: expanding horizons with innovative peptide vaccines and peptidomimetics |
| Q50926799 | Building better magic bullets--improving unconjugated monoclonal antibody therapy for cancer. |
| Q35817552 | Building better monoclonal antibody-based therapeutics. |
| Q36714370 | Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study |
| Q34775370 | Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer |
| Q92105345 | Cell-Free Co-Translational Approaches for Producing Mammalian Receptors: Expanding the Cell-Free Expression Toolbox Using Nanolipoproteins |
| Q38852051 | Cell-specific biomarkers and targeted biopharmaceuticals for breast cancer treatment |
| Q33434406 | Characterizing complex polysera produced by antigen-specific immunization through the use of affinity-selected mimotopes |
| Q35671133 | Chemopreventive activity of vitamin E in breast cancer: a focus on γ- and δ-tocopherol |
| Q90484961 | Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond |
| Q38038489 | Clinical trials and future potential of targeted therapy for ovarian cancer |
| Q37679938 | Colorectal cancer in review: the role of the EGFR pathway |
| Q35506684 | Combating HER2-overexpressing breast cancer through induction of calreticulin exposure by Tras-Permut CrossMab |
| Q37653981 | Combination of lapatinib with isothiocyanates overcomes drug resistance and inhibits migration of HER2 positive breast cancer cells |
| Q37046550 | Combination photoimmunotherapy with monoclonal antibodies recognizing different epitopes of human epidermal growth factor receptor 2: an assessment of phototherapeutic effect based on fluorescence molecular imaging |
| Q34787422 | Combination treatment with HER-2 and VEGF peptide mimics induces potent anti-tumor and anti-angiogenic responses in vitro and in vivo |
| Q41676912 | Combinatorial immunotherapy of sorafenib and blockade of programmed death-ligand 1 induces effective natural killer cell responses against hepatocellular carcinoma |
| Q36388501 | Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo |
| Q28542825 | Comparative analysis of evolutionarily conserved motifs of epidermal growth factor receptor 2 (HER2) predicts novel potential therapeutic epitopes |
| Q34560075 | Comparing antibody and small-molecule therapies for cancer |
| Q39563946 | Comparing domain interactions within antibody Fabs with kappa and lambda light chains |
| Q34473476 | Computational design of a CNT carrier for a high affinity bispecific anti-HER2 antibody based on trastuzumab and pertuzumab Fabs |
| Q41902817 | Conditions of tumor-associated antigens as a proper target for therapeutic antibodies against solid cancers |
| Q51696685 | Could precision-engineered peptide epitopes/vaccines be the key to a cancer cure? |
| Q64076747 | Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex |
| Q37250084 | Crystallization and preliminary crystallographic studies of the single-chain variable fragment of antibody chA21 in complex with an N-terminal fragment of ErbB2. |
| Q35164938 | Current neoadjuvant treatment options for HER2-positive breast cancer |
| Q49581539 | Current treatment of HER 2+ metastatic breast cancer |
| Q41915916 | Customizing the therapeutic response of signaling networks to promote antitumor responses by drug combinations. |
| Q64913714 | DNA-encoded bispecific T cell engagers and antibodies present long-term antitumor activity. |
| Q35999582 | Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer. |
| Q47665955 | Defining what matters most to patients |
| Q37741398 | Design and Synthesis of Near-Infrared Peptide for in Vivo Molecular Imaging of HER2 |
| Q36171074 | Design of a doxorubicin-peptidomimetic conjugate that targets HER2-positive cancer cells |
| Q50049638 | Design of cyclic and d-amino acids containing peptidomimetics for inhibition of protein-protein interactions of HER2-HER3. |
| Q24293331 | Design, synthesis and characterization of peptidomimetic conjugate of BODIPY targeting HER2 protein extracellular domain |
| Q33835904 | Design, synthesis, and docking studies of peptidomimetics based on HER2-herceptin binding site with potential antiproliferative activity against breast cancer cell lines |
| Q36847220 | Development and Characterization of a Humanized Anti-HER2 Antibody HuA21 with Potent Anti-Tumor Properties in Breast Cancer Cells |
| Q47103332 | Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment |
| Q64955074 | Differential Effects of Inhibitory and Stimulatory Anti-HER2 Monoclonal Antibodies on AKT/ERK Signaling Pathways |
| Q33642507 | Differential binding patterns of monoclonal antibody 2C4 to the ErbB3-p185her2/neu and the EGFR-p185her2/neu complexes |
| Q37139011 | Differential killing of CD56-expressing cells by drug-conjugated human antibodies targeting membrane-distal and membrane-proximal non-overlapping epitopes |
| Q40793036 | Dimerization-based control of cooperativity |
| Q100512363 | Direct stimulation of ERBB2 highlights a novel cytostatic signaling pathway driven by the receptor Thr701 phosphorylation |
| Q36088057 | Directed Evolution of Scanning Unnatural-Protease-Resistant (SUPR) Peptides for in Vivo Applications |
| Q33685019 | Discovery of an enzyme and substrate selective inhibitor of ADAM10 using an exosite-binding glycosylated substrate |
| Q41130070 | Discovery of epitopes for targeting the human epidermal growth factor receptor 2 (HER2) with antibodies |
| Q34151773 | Distribution of resting and ligand-bound ErbB1 and ErbB2 receptor tyrosine kinases in living cells using number and brightness analysis |
| Q29619825 | Diverse somatic mutation patterns and pathway alterations in human cancers |
| Q54200419 | Docking and molecular dynamics simulation study of EGFR1 with EGF-like peptides to understand molecular interactions. |
| Q100237092 | Drug-mediated inhibition of ERBB2 signaling |
| Q37940203 | Dual HER2-targeted approaches in HER2-positive breast cancer |
| Q34009045 | Dual human epidermal growth factor receptor 2 blockade for the treatment of HER2-positive breast cancer |
| Q92487014 | Dual-labeled pertuzumab for multimodality image-guided ovarian tumor resection |
| Q37234153 | Dynamic analysis of the epidermal growth factor (EGF) receptor-ErbB2-ErbB3 protein network by luciferase fragment complementation imaging |
| Q39198504 | EGFR Family Members' Regulation of Autophagy Is at a Crossroads of Cell Survival and Death in Cancer |
| Q36947038 | EGFR, HER2 and VEGF pathways: validated targets for cancer treatment |
| Q26863231 | EGFR/HER-targeted therapeutics in ovarian cancer |
| Q89810503 | ELISA assay employing epitope-specific monoclonal antibodies to quantify circulating HER2 with potential application in monitoring cancer patients undergoing therapy with trastuzumab |
| Q29619520 | ERBB receptors and cancer: the complexity of targeted inhibitors |
| Q33601653 | ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics |
| Q100158107 | ERBB2 binds pertuzumab |
| Q39686854 | Early response to ErbB2 over-expression in polarized Caco-2 cells involves partial segregation from ErbB3 by relocalization to the apical surface and initiation of survival signaling |
| Q24311715 | Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization |
| Q39816545 | Effects of Trastuzumab Emtansine (T-DM1) on QT Interval and Safety of Pertuzumab Plus T-DM1 in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer |
| Q28254919 | Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial |
| Q37893414 | Emerging antibody combinations in oncology |
| Q38119307 | Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab |
| Q38284597 | Emerging mAbs for the treatment of esophagogastric cancer |
| Q30839490 | Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin |
| Q35145024 | Engineered bivalent ligands to bias ErbB receptor-mediated signaling and phenotypes. |
| Q92768203 | Engineering a HER2-specific antibody-drug conjugate to increase lysosomal delivery and therapeutic efficacy |
| Q37698914 | Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells |
| Q38923245 | Enhancement of cell type specificity by quantitative modulation of a chimeric ligand |
| Q37101643 | Epidermal growth factor receptor and cancer: control of oncogenic signalling by endocytosis |
| Q24529941 | Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface |
| Q36302860 | Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer |
| Q47598173 | Epidermal growth factor receptors containing a single tyrosine in their C-terminal tail bind different effector molecules and are signaling-competent |
| Q49671739 | Epitope Mapping of Human HER2 Specific Mouse Monoclonal Antibodies Using Recombinant Extracellular Subdomains |
| Q38729111 | ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology |
| Q47974787 | ErbB Receptors and Cancer |
| Q37970020 | ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective |
| Q37145440 | ErbB receptors, their ligands, and the consequences of their activation and inhibition in the myocardium |
| Q37200831 | ErbB3 downregulation enhances luminal breast tumor response to antiestrogens |
| Q34485373 | Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study |
| Q34694211 | Evaluation of the anti-HER2 C6.5 diabody as a PET radiotracer to monitor HER2 status and predict response to trastuzumab treatment |
| Q37643985 | Evolving novel anti-HER2 strategies |
| Q34745805 | Expression of NRG1 and its receptors in human bladder cancer |
| Q26746081 | First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces? |
| Q39011393 | Functional expression of a single-chain antibody fragment against human epidermal growth factor receptor 2 (HER2) in Escherichia coli |
| Q36170837 | Functional isolation of activated and unilaterally phosphorylated heterodimers of ERBB2 and ERBB3 as scaffolds in ligand-dependent signaling |
| Q33907971 | Generation and characterization of peptide mimotopes specific for anti ErbB-2 monoclonal antibodies |
| Q27688974 | Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface |
| Q36184584 | Genetic and biochemical alterations in non-small cell lung cancer |
| Q34079994 | Genome wide proteomics of ERBB2 and EGFR and other oncogenic pathways in inflammatory breast cancer |
| Q37650402 | HER-dimerization inhibitors: evaluating pertuzumab in women's cancers |
| Q33514127 | HER/ErbB receptor interactions and signaling patterns in human mammary epithelial cells |
| Q28237833 | HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer |
| Q33686182 | HER2 Pro1170Ala polymorphism is associated with decreased survival rate in HER2-negative breast cancer |
| Q37303196 | HER2 breast cancer therapies: a review |
| Q47097049 | HER2 exon 27 mutations predict worse survival of breast cancer patients, especially in HER2-negative patients. |
| Q57109545 | HER2 inhibition in gastro-oesophageal cancer: A review drawing on lessons learned from breast cancer |
| Q37698925 | HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design |
| Q36953374 | HER2 targeted therapy in breast cancer...beyond Herceptin |
| Q35749374 | HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks |
| Q35633712 | HER2 therapy: molecular mechanisms of trastuzumab resistance. |
| Q39147155 | HER2-Orientated Therapy in Early and Metastatic Breast Cancer |
| Q36839672 | HER2-positive breast cancer: current and future treatment strategies |
| Q37778843 | HER3 mRNA as a predictive biomarker in anticancer therapy |
| Q50949577 | HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients. |
| Q44153213 | Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer |
| Q42088721 | Her2 activation mechanism reflects evolutionary preservation of asymmetric ectodomain dimers in the human EGFR family |
| Q50130809 | Heterologous human/rat HER2-specific exosome-targeted T cell vaccine stimulates potent humoral and CTL responses leading to enhanced circumvention of HER2 tolerance in double transgenic HLA-A2/HER2 mice |
| Q27349722 | High affinity antigen recognition of the dual specific variants of herceptin is entropy-driven in spite of structural plasticity |
| Q37257182 | High cell-surface density of HER2 deforms cell membranes |
| Q57281213 | High-resolution glycosylation site-engineering method identifies MICA epitope critical for shedding inhibition activity of anti-MICA antibodies |
| Q37826199 | Hitting multiple targets in HER2-positive breast cancer: proof of principle or therapeutic opportunity? |
| Q64119068 | How Structural Biologists and the Protein Data Bank Contributed to Recent FDA New Drug Approvals |
| Q90211923 | Human Domain Antibodies to Conserved Epitopes on HER2 Potently Inhibit Growth of HER2-Overexpressing Human Breast Cancer Cells In Vitro |
| Q26777681 | Human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic options |
| Q34166042 | Human epidermal growth factor receptor 2-targeted therapies in breast cancer |
| Q27025863 | Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer |
| Q64079004 | Hydrodynamic and Electrophoretic Properties of Trastuzumab/HER2 Extracellular Domain Complexes as Revealed by Experimental Techniques and Computational Simulations |
| Q92533784 | Identification of an Activating Mutation in the Extracellular Domain of HER2 Conferring Resistance to Pertuzumab |
| Q35168105 | Identification of anti-ErbB2 dual variable domain immunoglobulin (DVD-Ig™) proteins with unique activities |
| Q33720335 | Identification of prolidase as a high affinity ligand of the ErbB2 receptor and its regulation of ErbB2 signaling and cell growth |
| Q34650345 | Identification of relevant conformational epitopes on the HER2 oncoprotein by using Large Fragment Phage Display (LFPD). |
| Q38137829 | Imaging EGFR and HER2 by PET and SPECT: a review |
| Q34140043 | Immunological Approaches in the Treatment of Metastasized Breast Cancer |
| Q38787696 | Immunotherapy for breast cancer: past, present, and future |
| Q36388489 | Immunotherapy with HER-2 and VEGF peptide mimics plus metronomic paclitaxel causes superior antineoplastic effects in transplantable and transgenic mouse models of human breast cancer |
| Q89752884 | Impact of the Protein Data Bank on antineoplastic approvals |
| Q34574191 | Improvement of mass spectrometry analysis of glycoproteins by MALDI-MS using 3-aminoquinoline/α-cyano-4-hydroxycinnamic acid |
| Q49581531 | Improving patient care: expert nursing and service development |
| Q37998453 | Improving treatment of HER2-positive cancers: opportunities and challenges |
| Q36425044 | In silico design, construction and cloning of Trastuzumab humanized monoclonal antibody: A possible biosimilar for Herceptin |
| Q36647014 | In vivo fluorescence lifetime imaging for monitoring the efficacy of the cancer treatment |
| Q38382775 | Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab |
| Q38266772 | Infection risk in breast cancer patients treated with trastuzumab: a systematic review and meta-analysis |
| Q35195881 | Inhibiting EGFR dimerization using triazolyl-bridged dimerization arm mimics |
| Q35733827 | Inhibition of ERBB2-overexpressing Tumors by Recombinant Human Prolidase and Its Enzymatically Inactive Mutant |
| Q36610755 | Inhibition of protein-protein interaction of HER2-EGFR and HER2-HER3 by a rationally designed peptidomimetic |
| Q36625236 | Inhibitors of signal transduction protein kinases as targets for cancer therapy |
| Q27683825 | Insights into HER2 signaling from step-by-step optimization of anti-HER2 antibodies |
| Q37320814 | Interaction of antibodies with ErbB receptor extracellular regions |
| Q43975038 | Interactions between anti-ErbB2 antibody A21 and the ErbB2 extracellular domain provide a basis for improving A21 affinity |
| Q27315979 | Intermolecular biparatopic trapping of ErbB2 prevents compensatory activation of PI3K/AKT via RAS-p110 crosstalk |
| Q36088788 | Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications |
| Q38340008 | Investigational therapies currently in Phase II clinical trials for the treatment of pelvic serous carcinomas. |
| Q38221886 | Investigational therapies targeting the ErbB family in oesophagogastric cancer |
| Q54207871 | LMO1 is a novel oncogene in colorectal cancer and its overexpression is a new predictive marker for anti-EGFR therapy. |
| Q38974183 | LMO1 is a novel oncogene in lung cancer, and its overexpression is a new predictive marker for anti-EGFR therapy |
| Q38940251 | Lhx3 is required to maintain cancer cell development of high-grade oligodendroglioma |
| Q24321567 | Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941 |
| Q37154122 | Ligand-induced ErbB receptor dimerization |
| Q39183138 | Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab |
| Q37690877 | Localisation Microscopy of Breast Epithelial ErbB-2 Receptors and Gap Junctions: Trafficking after γ-Irradiation, Neuregulin-1β, and Trastuzumab Application. |
| Q38768387 | Macrophage-Mediated Trogocytosis Leads to Death of Antibody-Opsonized Tumor Cells |
| Q36547047 | Major clinical research advances in gynecologic cancer in 2012. |
| Q37686055 | Management of breast cancer with targeted agents: importance of heterogeneity. [corrected]. |
| Q38233292 | Management of patients with HER2-positive metastatic breast cancer: is there an optimal sequence of HER2-directed approaches? |
| Q27650259 | Matuzumab Binding to EGFR Prevents the Conformational Rearrangement Required for Dimerization |
| Q57105786 | Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer |
| Q40009294 | Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members |
| Q28385366 | Mechanisms of action of therapeutic antibodies for cancer |
| Q36472437 | Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer |
| Q34220190 | Methodologies for the isolation of alternative binders with improved clinical potentiality over conventional antibodies |
| Q53078543 | Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes. |
| Q41676872 | Mode of action of pertuzumab in combination with trastuzumab plus docetaxel therapy in a HER2-positive breast cancer xenograft model |
| Q31129446 | Model-based analysis of HER activation in cells co-expressing EGFR, HER2 and HER3 |
| Q28072513 | Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer |
| Q36440214 | Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer |
| Q35176414 | Molecular architecture of the ErbB2 extracellular domain homodimer |
| Q38548814 | Molecular dynamics simulations of transitions for ECD epidermal growth factor receptors show key differences between human and drosophila forms of the receptors. |
| Q36396421 | Molecular mechanisms of cardiotoxicity induced by ErbB receptor inhibitor cancer therapeutics |
| Q28072433 | Molecular targeted therapy for the treatment of gastric cancer |
| Q35686002 | Monitoring serum HER2 levels in breast cancer patients |
| Q27025966 | Monoclonal antibodies for the treatment of cancer |
| Q38253815 | Monoclonal antibodies for the treatment of non-haematological tumours: update of an expanding scenario. |
| Q35659915 | Monoclonal antibodies in gynecological cancer: a critical point of view |
| Q37355568 | Monoclonal antibodies in the treatment of pancreatic cancer. |
| Q38078400 | Monoclonal antibodies therapies for ovarian cancer |
| Q34111693 | Monoclonal antibodies: versatile platforms for cancer immunotherapy |
| Q36961106 | Monoclonal antibody mechanisms of action in cancer. |
| Q81189032 | Monoclonal antibody therapy of cancer |
| Q36066157 | Monoclonal antibody therapy of ovarian cancer |
| Q36586901 | Monoclonal antibody-based targeted therapy in breast cancer: current status and future directions |
| Q39379086 | Monoclonal antibody-induced ErbB3 receptor internalization and degradation inhibits growth and migration of human melanoma cells. |
| Q34698008 | Muc4-ErbB2 complex formation and signaling in polarized CACO-2 epithelial cells indicate that Muc4 acts as an unorthodox ligand for ErbB2 |
| Q36810717 | Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006 |
| Q36914142 | Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer |
| Q36809609 | Neoadjuvant human epidermal growth factor receptor-2 targeted therapy in patients with locally advanced breast cancer. |
| Q64981225 | Neoadjuvant zoledronic acid for HER2-positive breast cancer: the Zo-NAnTax trial. |
| Q26865260 | Newer therapies for the treatment of metastatic breast cancer: a clinical update |
| Q90609780 | Not all therapeutic antibody isotypes are equal: the case of IgM versus IgG in Pertuzumab and Trastuzumab |
| Q36641436 | Novel HER2 aptamer selectively delivers cytotoxic drug to HER2-positive breast cancer cells in vitro |
| Q36356248 | Novel HER3/MUC4 oncogenic signaling aggravates the tumorigenic phenotypes of pancreatic cancer cells |
| Q35533514 | Novel Peptidomimetics for Inhibition of HER2:HER3 Heterodimerization in HER2-Positive Breast Cancer |
| Q34433064 | Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-α. |
| Q37523202 | Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. |
| Q57578958 | Novel therapeutics in breast cancer—Looking to the future |
| Q57106864 | Novel treatment strategies for patients with HER2-positive breast cancer who do not benefit from current targeted therapy drugs |
| Q47646487 | Obtaining and characterization of monoclonal antibodies against recombinant extracellular domain of human epidermal growth factor receptor 2. |
| Q50648214 | Oncogenicity of LHX4 in colorectal cancer through Wnt/β-catenin/TCF4 cascade. |
| Q35569418 | One target, different effects: a comparison of distinct therapeutic antibodies against the same targets |
| Q30376023 | Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative me |
| Q38017732 | Overcoming treatment resistance in HER2-positive breast cancer: potential strategies. |
| Q38390565 | Overexpression and gene amplification of EGFR, HER2, and HER3 in biliary tract carcinomas, and the possibility for therapy with the HER2-targeting antibody pertuzumab |
| Q34435089 | Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan. |
| Q36170761 | Pari passu dimers of dimers |
| Q40486229 | Parsing ERK activation reveals quantitatively equivalent contributions from epidermal growth factor receptor and HER2 in human mammary epithelial cells |
| Q33562598 | Peptide probes derived from pertuzumab by molecular dynamics modeling for HER2 positive tumor imaging |
| Q36116250 | Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy |
| Q91719970 | Peptide-Based Vaccines: Current Progress and Future Challenges |
| Q34664129 | Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer |
| Q64934294 | Personalized medicine in breast cancer: pharmacogenomics approaches. |
| Q38848389 | Perspectives of HER2-targeting in gastric and esophageal cancer |
| Q38093224 | Pertuzumab : evolving therapeutic strategies in the management of HER2-overexpressing breast cancer |
| Q37148772 | Pertuzumab Increases 17-AAG-Induced Degradation of ErbB2, and This Effect Is Further Increased by Combining Pertuzumab with Trastuzumab |
| Q33364587 | Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle |
| Q39701009 | Pertuzumab and trastuzumab: the rationale way to synergy |
| Q38219674 | Pertuzumab for the treatment of breast cancer |
| Q38776876 | Pertuzumab for the treatment of breast cancer: a safety review |
| Q38132527 | Pertuzumab for the treatment of human epidermal growth factor receptor type 2-positive metastatic breast cancer |
| Q38132237 | Pertuzumab for the treatment of metastatic breast cancer |
| Q36336483 | Pertuzumab for the treatment of patients with human epidermal growth factor receptor 2-positive breast cancer in Japan |
| Q37205749 | Pertuzumab for the treatment of patients with previously untreated HER2-positive metastatic breast cancer |
| Q33618685 | Pertuzumab in Combination with Trastuzumab and Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Safety, Efficacy, and Progression Free Survival |
| Q38286163 | Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer |
| Q38653309 | Pertuzumab in gastrointestinal cancer |
| Q33680109 | Pertuzumab in human epidermal growth-factor receptor 2-positive breast cancer: clinical and economic considerations |
| Q27851691 | Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer |
| Q33827808 | Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. |
| Q38126859 | Pertuzumab: a new targeted therapy for HER2-positive metastatic breast cancer |
| Q38132047 | Pertuzumab: a review of its use for first-line combination treatment of HER2-positive metastatic breast cancer |
| Q37982433 | Pertuzumab: in the first-line treatment of HER2-positive metastatic breast cancer |
| Q38036549 | Pertuzumab: new hope for patients with HER2-positive breast cancer |
| Q50876579 | Phage Display Selection, In Vitro Characterization, and Correlative PET Imaging of a Novel HER3 Peptide. |
| Q37639279 | Pharmacokinetic and exposure-response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer |
| Q38573858 | Pharmacokinetics, pharmacodynamics and clinical efficacy of pertuzumab in breast cancer therapy |
| Q36687107 | Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer |
| Q37412304 | Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors |
| Q37140621 | Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese patients with solid tumors |
| Q34193975 | Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study |
| Q47307197 | Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer |
| Q37163797 | Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy |
| Q46216597 | Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors. |
| Q37658764 | Potential of ErbB4 antibodies for cancer therapy. |
| Q37687975 | Precision medicine and personalized breast cancer: combination pertuzumab therapy |
| Q28078658 | Precision targeted therapy of ovarian cancer |
| Q100568993 | Predicting the molecular mechanism of EGFR Domain II dimer binding interface by machine learning to identify potent small molecule inhibitor for treatment of cancer |
| Q35707409 | Predominant structural configuration of natural antibody repertoires enables potent antibody responses against protein antigens |
| Q34274925 | Present and future evolution of advanced breast cancer therapy |
| Q42810614 | Principles and method of action of targeted therapies |
| Q35677713 | Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer |
| Q46935318 | Prolonged EGFR signaling by ERBB2-mediated sequestration at the plasma membrane |
| Q41838529 | Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies |
| Q36501235 | Protein therapeutics: new applications for pharmacogenetics |
| Q55015029 | Proteolytic single hinge cleavage of pertuzumab impairs its Fc effector function and antitumor activity in vitro and in vivo. |
| Q55715013 | Quantification of Circulating Cancer Biomarkers via Sensitive Topographic Measurements on Single Binder Nanoarrays. |
| Q48585812 | Quantitating ADCC against adherent cells: Impedance-based detection is superior to release, membrane permeability, or caspase activation assays in resolving antibody dose response |
| Q35559032 | Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action |
| Q39980973 | Quantitative characterization of the large-scale association of ErbB1 and ErbB2 by flow cytometric homo-FRET measurements. |
| Q35461504 | RETRACTED: Silencing EGFR/HER3 signaling with a novel anti-EGFR domain II/IV antibody |
| Q37360162 | Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer |
| Q36491838 | Recent advances in targeting regulators of apoptosis in cancer cells for therapeutic gain |
| Q64055629 | Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms |
| Q36139512 | Recombinant approaches to IgG-like bispecific antibodies |
| Q34532338 | Reorienting the Fab domains of trastuzumab results in potent HER2 activators |
| Q35591518 | Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications |
| Q89634778 | Restricted epitope specificity determined by variable region germline segment pairing in rodent antibody repertoires |
| Q47996245 | Rigidity of the extracellular part of HER2: Evidence from engineering subdomain interfaces and shared-helix DARPin-DARPin fusions |
| Q47100005 | Risk Factors and Preventions of Breast Cancer |
| Q38025317 | Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis |
| Q35077315 | Risk of severe diarrhea with dual anti-HER2 therapies: a meta-analysis |
| Q37724647 | Role of human epidermal growth factor receptor 2 in gastric cancer: biological and pharmacological aspects |
| Q27002386 | Role of pertuzumab in the treatment of HER2-positive breast cancer |
| Q37355370 | Role of trastuzumab in the management of HER2-positive metastatic breast cancer. |
| Q36202795 | Roles for neuregulins in human cancer. |
| Q38977452 | SOX10 is a novel oncogene in hepatocellular carcinoma through Wnt/β-catenin/TCF4 cascade |
| Q43863582 | SOX2 oncogenes amplified and operate to activate AKT signaling in gastric cancer and predict immunotherapy responsiveness |
| Q55018821 | Safety Assessment of Neoadjuvant Pertuzumab Combined with Trastuzumab in Nonmetastatic HER2-Positive Breast Cancer in Postmenopausal Elderly Women of South Asia. |
| Q37498654 | Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results |
| Q33829773 | Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA. |
| Q38780521 | Septin oligomerization regulates persistent expression of ErbB2/HER2 in gastric cancer cells |
| Q37316604 | Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family |
| Q30412166 | Silicon particles as trojan horses for potential cancer therapy. |
| Q44923102 | Simulation of homology models for the extracellular domains (ECD) of ErbB3, ErbB4 and the ErbB2-ErbB3 complex in their active conformations |
| Q92961960 | Single-step Protein A and Protein G avidity purification methods to support bispecific antibody discovery and development |
| Q38151570 | Somatic alterations as the basis for resistance to targeted therapies |
| Q37235024 | Somatic pharmacogenomics in cancer |
| Q35864802 | Special Agents Hunting Down Women Silent Killer: The Emerging Role of the p38α Kinase |
| Q24293655 | Spontaneous and pronase-induced HER2 truncation increases the trastuzumab binding capacity of breast cancer tissues and cell lines |
| Q37655585 | State of the art in anti-cancer mAbs. |
| Q36293541 | Strategies and methodologies for identifying molecular targets in sarcomas and other tumors |
| Q36143159 | Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs |
| Q27670462 | Structural Insights into the Down-regulation of Overexpressed p185her2/neu Protein of Transformed Cells by the Antibody chA21 |
| Q27664013 | Structural basis for high-affinity HER2 receptor binding by an engineered protein |
| Q41612592 | Structural basis of a novel heterodimeric Fc for bispecific antibody production |
| Q34634742 | Structural model for the interaction of a designed Ankyrin Repeat Protein with the human epidermal growth factor receptor 2. |
| Q35925840 | Structure and function of the epidermal growth factor (EGF/ErbB) family of receptors |
| Q35185574 | Structure-activity relationship of conformationally constrained peptidomimetics for antiproliferative activity in HER2-overexpressing breast cancer cell lines |
| Q37721805 | Structure-activity relationships of peptidomimetics that inhibit PPI of HER2-HER3. |
| Q35942583 | Structure-based Design of Peptides with High Affinity and Specificity to HER2 Positive Tumors |
| Q37197992 | Structure-based view of epidermal growth factor receptor regulation |
| Q83200641 | Suppression of breast cancer cell growth by a monoclonal antibody targeting cleavable ErbB4 isoforms |
| Q35558065 | Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism |
| Q33769117 | Synthesis and biochemical characterization of EGF receptor in a water-soluble membrane model system |
| Q37271928 | Systemic cancer therapy: evolution over the last 60 years |
| Q42109090 | Systems analysis of drug-induced receptor tyrosine kinase reprogramming following targeted mono- and combination anti-cancer therapy. |
| Q37191051 | Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients |
| Q37795802 | Targeted Agents in Ovarian Cancer |
| Q47559665 | Targeted Therapies Against Growth Factor Signaling in Breast Cancer |
| Q35687574 | Targeted Therapies in Breast Cancer: Implications for Advanced Oncology Practice. |
| Q36174805 | Targeted cancer therapy--are the days of systemic chemotherapy numbered? |
| Q36150842 | Targeted therapies for prostate cancer |
| Q34878868 | Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action |
| Q42571051 | Targeted therapy in HER2-positive breast cancer |
| Q58568282 | Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer |
| Q55071512 | Targeting ErbB-2 nuclear localization and function inhibits breast cancer growth and overcomes trastuzumab resistance. |
| Q36114852 | Targeting HER2 Positive Breast Cancer with Chemopreventive Agents |
| Q49579954 | Targeting HER2 by Combination Therapies. |
| Q37768460 | Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer |
| Q36613969 | Targeting epidermal growth factor receptor signaling in the treatment of head and neck cancer |
| Q26822568 | Targeting extracellular domains D4 and D7 of vascular endothelial growth factor receptor 2 reveals allosteric receptor regulatory sites |
| Q64064458 | Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer |
| Q35987779 | Targeting protein kinases in cancer therapy: a success? |
| Q92571116 | Temporal Modulation of HER2 Membrane Availability Increases Pertuzumab Uptake and Pretargeted Molecular Imaging of Gastric Tumors |
| Q54498075 | The ERBB network: at last, cancer therapy meets systems biology. |
| Q37135372 | The ERBB3 receptor in cancer and cancer gene therapy |
| Q64084185 | The Effects of Pertuzumab and Its Combination with Trastuzumab on HER2 Homodimerization and Phosphorylation |
| Q33829742 | The European Medicines Agency Review of Pertuzumab for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer: summary of the scientific assessment of the committee for medicinal products for hu |
| Q34558080 | The HER family and cancer: emerging molecular mechanisms and therapeutic targets |
| Q38237727 | The Mysterious Ways of ErbB2/HER2 Trafficking |
| Q34096063 | The Role of Targeted Agents in the Treatment of Metastatic Breast Cancer. |
| Q36064912 | The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer |
| Q38210070 | The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey |
| Q37327307 | The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity |
| Q34692233 | The epidermal growth factor receptor family: biology driving targeted therapeutics |
| Q36423909 | The expression of KIT receptor dimers in gastrointestinal stromal tumors independent of c-kit mutation and SCF expression is associated with high-risk stratification |
| Q24536067 | The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand |
| Q38698199 | The impact of structural biology in medicine illustrated with four case studies |
| Q38927764 | The level of HER2 expression is a predictor of antibody-HER2 trafficking behavior in cancer cells |
| Q37954671 | The paradigm of personalized therapy in oncology |
| Q39433244 | The peptide derived from erbB2 auto-inhibitor herstatin shared in the same epitope and function with functional antibody 2C4. |
| Q38981780 | The prospect of patritumab for treating non-small cell lung cancer |
| Q34054213 | The role of HER2 in cancer therapy and targeted drug delivery |
| Q24656159 | The role of HER2-targeted therapies in women with HER2-overexpressing metastatic breast cancer |
| Q37209533 | The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2. |
| Q94527304 | The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies |
| Q92542925 | Therapeutic and Mechanistic Perspectives of Protein Complexes in Breast Cancer |
| Q38214802 | Therapeutic targeting of ERBB2 in breast cancer: understanding resistance in the laboratory and combating it in the clinic |
| Q34719632 | Time-resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using monoclonal antibodies |
| Q24313194 | Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab |
| Q37704902 | Transmembrane helix-helix interactions involved in ErbB receptor signaling. |
| Q89727324 | Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond |
| Q54573289 | Trastuzumab and lapatinib modulation of HER2 tyrosine/threonine phosphorylation and cell signaling. |
| Q38393922 | Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study. |
| Q37387449 | Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancer |
| Q92886181 | Trastuzumab in the Treatment of Pregnant Breast Cancer Patients - an Overview of the Literature |
| Q37846228 | Trastuzumab: a new treatment option for HER2-positive metastatic gastric and gastroesophageal junction cancer |
| Q36832109 | Trastuzumab: triumphs and tribulations |
| Q37799950 | Treatment of HER2-overexpressing breast cancer |
| Q37962332 | Treatment of HER2-positive breast cancer: current status and future perspectives. |
| Q36275971 | Treatment of HER2-positive metastatic breast cancer following initial progression |
| Q28081124 | Treatment of early-stage HER2+ breast cancer-an evolving field |
| Q40138970 | Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy |
| Q36402698 | Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling |
| Q38376822 | Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study |
| Q35895143 | Two dimensions in targeting HER2. |
| Q38123762 | Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer |
| Q48263612 | Using Genome Sequence to Enable the Design of Medicines and Chemical Probes. |
| Q28480572 | Using functional signatures to identify repositioned drugs for breast, myelogenous leukemia and prostate cancer |
| Q37244237 | Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study |
| Q38977752 | Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway |
| Q37643945 | erbB3 is an active tyrosine kinase capable of homo- and heterointeractions |
| Q48465476 | mAb806 binding to epidermal growth factor receptor: a computational study |